Discover MSA Safety's Q4 2024 earnings insights, including strong margin growth, connected device innovations, and 2025 strategies amid dynamic ...

and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech ...

Consensus for 2025 revenue is $1.87B. Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...

Alterity Therapeutics Limited (market cap: $40 million), a pharmaceutical company specializing in the development of therapeutic drugs, has secured A$40 million in funding to advance the development ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

Sam Altman, pictured at President Donald Trump's inauguration, is contributing to another round of funding for Retro Biosciences. © 2025 Fortune Media IP Limited ...

BEIJING, Feb 14 (Reuters) - China issued guidelines on Friday to promote biotech cultivation, focusing on gene-editing tools and developing new wheat, corn, and soybean varieties, as part of ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

The synthetic chromosome includes features that enable researchers to generate genetic diversity on demand, accelerating the development of yeasts with enhanced capabilities for biotechnology ...